JADO Reports Clinical Proof Of Concept With Raft Modulator In Atopic Dermatitis

JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis. TF002, a topical formulation of miltefosine, exerts its anti-inflammatory activity via RAFT modulation. RAFTS are sub-compartments in the lipid membrane of cells that play a role in the complex physiological processes, such as immune response.

More: continued here

Filed under: Clinical Trials on February 19th, 2008